TrialClinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Trial details
- Registry ID
- NCT06767514
- Phase
- Phase 3
Drug research
Pembrolizumab Injection
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as KEYTRUDA®
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1NCT06767514 | Summit Therapeutics | Phase 3 | Recruiting | 2028-04Estimated |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC PatientsNCT05899608 | Summit Therapeutics | Phase 3 | Recruiting | 2028-12-31Estimated |
| Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinNCT04387461 | CGON | Phase 2 | Completed | 2023-03-07Actual |
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
Trial details
- Registry ID
- NCT05899608
- Phase
- Phase 3
Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin
Trial details
- Registry ID
- NCT04387461
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |